论文部分内容阅读
目的对比观察短期应用凯时(LIPOPGFl)与灯盏花注射液降低2型糖尿病早期肾病患者尿微量白蛋白的临床疗效。方法将60例2型糖尿病肾病3期(微量白蛋白尿期)患者,年龄41~75岁,男27例,女33例,随机分为两组即凯时治疗组和灯盏花治疗组。两组病人均给予控制饮食和药物治疗(口服降糖药或胰岛素)。选用非ACEI及ARB类降压药物降压。且两组病人的尿微量白蛋白,性别,年龄,体重指数,病程,血糖,血压等方面比较在统计学上无显著差异(P>0.05)。待血糖达标后,血压理想平稳,两组病人分别给予凯时和灯盏花治疗,每日1次连续14天。两周后比较治疗前后两组病人24小时尿微量白蛋白的变化。结果凯时组与灯盏花组两组治疗前后UAE分别都显著下降(P<0.01)。凯时组较灯盏花组治疗后UAE下降更显著,两组治疗后UAE组间有显著差异(P<0.05)。结论凯时及灯盏花在降低早期糖尿病肾病病人尿微量白蛋白均具显著疗效,而前者比后者尤为突出。
Objective To compare the clinical effects of short-term use of LIPOPGFl and Erigeron Injection in the treatment of urinary albumin in type 2 diabetic patients with early nephropathy. Methods A total of 60 patients with type 2 diabetic nephropathy (microalbuminuria), aged from 41 to 75 years, 27 males and 33 females, were randomly divided into two groups, namely, Kai-shi treatment group and Dengzhanhua treatment group. Both groups were given controlled diet and medication (oral hypoglycemic agents or insulin). Choose non-ACEI and ARB antihypertensive drugs blood pressure. Urine microalbumin, gender, age, body mass index, duration of disease, blood glucose, blood pressure and other aspects of the two groups were statistically no significant difference (P> 0.05). Blood glucose to be until the standard, the ideal blood pressure steady, two groups of patients were given Kay hours and Erigeron treatment, once daily for 14 consecutive days. Two weeks later, the changes of 24-hour urinary albumin before and after treatment were compared between two groups. Results The UAE of Kai-shi group and Erigeron group decreased significantly before and after treatment (P <0.01). The UAE decreased more significantly in the Kaye group than in the Erigeron breviscapus group, and there was significant difference between the UAE group and the UAE group after treatment (P <0.05). Conclusions Kay and Erigeron Breviscapus in reducing the early diabetic nephropathy patients with urinary albumin have a significant effect, while the former is more prominent than the latter.